The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Poon Christine A since 2015.
This trader's CIK number is 1189014.
At the time of last reporting, Poon Christine A was the Director of Regeneron Pharmaceuticals, Inc.. (stock ticker symbol REGN).
Also see all insider trading activities at Regeneron Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | REGN | 0 | $0 | 6,500 | $4,256,947 | 9,212 | $4,790,332 |
| 2024 | REGN | 0 | $0 | 10,838 | $12,554,587 | 10,838 | $4,479,670 |
| 2023 | REGN | 0 | $0 | 12,280 | $10,309,477 | 12,280 | $3,360,667 |
| 2022 | REGN | 0 | $0 | 15,000 | $9,313,050 | 15,000 | $2,667,300 |
| 2021 | REGN | 0 | $0 | 15,000 | $10,011,975 | 15,000 | $856,650 |
| 2020 | REGN | 0 | $0 | 40,000 | $24,040,920 | 40,000 | $1,177,400 |
| 2015 | REGN | 0 | $0 | 112 | $63,186 | 470 | $128,624 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | PRU | 0 | $0 | 0 | $0 | 1,321 | $0 |
| 2024 | PRU | 0 | $0 | 0 | $0 | 1,935 | $0 |
| 2023 | PRU | 0 | $0 | 0 | $0 | 1,517 | $0 |
| 2022 | PRU | 0 | $0 | 0 | $0 | 1,494 | $0 |
| 2021 | PRU | 0 | $0 | 0 | $0 | 2,933 | $0 |
| 2020 | PRU | 0 | $0 | 0 | $0 | 1,607 | $0 |
| 2019 | PRU | 0 | $0 | 0 | $0 | 1,558 | $0 |
| 2018 | PRU | 0 | $0 | 0 | $0 | 1,431 | $0 |
| 2017 | PRU | 0 | $0 | 0 | $0 | 2,006 | $0 |
| 2016 | PRU | 0 | $0 | 0 | $0 | 1,795 | $0 |
| 2015 | PRU | 0 | $0 | 0 | $0 | 1,821 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | NBIX | 0 | $0 | 0 | $0 | 1,435 | $0 |
1. Regeneron Pharmaceuticals, Inc. (REGN)
2. Prudential Financial Inc (PRU)
3. Neurocrine Biosciences Inc (NBIX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-10-29 | REGN | Option Ex | 6,500 | 520.01 | 3,380,065 |
| 2025-10-30 | REGN | Option Ex | 2,712 | 520.01 | 1,410,267 |
| 2025-10-29 | REGN | Sale | 6,500 | 654.91 | 4,256,947 |
| 2024-08-15 | REGN | Sale | 10,838 | 1,158.39 | 12,554,587 |
| 2024-08-15 | REGN | Option Ex | 10,838 | 413.33 | 4,479,670 |
| 2023-08-23 | REGN | Option Ex | 12,280 | 273.67 | 3,360,667 |
| 2023-08-23 | REGN | Sale | 12,280 | 839.53 | 10,309,477 |
| 2022-08-09 | REGN | Sale | 15,000 | 620.87 | 9,313,050 |
| 2022-08-09 | REGN | Option Ex | 15,000 | 177.82 | 2,667,300 |
| 2021-08-27 | REGN | Option Ex | 15,000 | 57.11 | 856,650 |
| 2021-08-27 | REGN | Sale | 15,000 | 667.47 | 10,011,975 |
| 2020-08-28 | REGN | Sale | 40,000 | 601.02 | 24,040,920 |
| 2020-08-28 | REGN | Option Ex | 40,000 | 29.43 | 1,177,400 |
| 2015-08-11 | REGN | Option Ex | 470 | 273.67 | 128,624 |
| 2015-08-12 | REGN | Sale | 112 | 564.16 | 63,186 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-13 | PRU | Option Ex | 1,321 | .00 | 0 |
| 2024-05-09 | PRU | Option Ex | 1,935 | .00 | 0 |
| 2023-05-09 | PRU | Option Ex | 1,517 | .00 | 0 |
| 2022-05-10 | PRU | Option Ex | 1,494 | .00 | 0 |
| 2021-05-11 | PRU | Option Ex | 2,933 | .00 | 0 |
| 2020-05-12 | PRU | Option Ex | 1,607 | .00 | 0 |
| 2019-05-08 | PRU | Option Ex | 1,558 | .00 | 0 |
| 2018-05-08 | PRU | Option Ex | 1,431 | .00 | 0 |
| 2017-05-09 | PRU | Option Ex | 2,006 | .00 | 0 |
| 2016-05-10 | PRU | Option Ex | 1,795 | .00 | 0 |
| 2015-05-12 | PRU | Option Ex | 1,821 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-22 | NBIX | Option Ex | 1,435 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Poon Christine A (Director of Regeneron Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.